BeStock  
Stocks › Biotechnology › IMMX

Immix Biopharma IMMX

US equityMarket cap rank #3420Biotechnology
$9.49 −$0.15 (-1.56%)
Pre-market · Oct 8, 8:50 am ET · After hours $9.49 0.00%
Open$9.50
Prev close$9.64
Day range$9.40 – $9.69
Volume1.38M
Market cap$788.42M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$12.46M-85.4% YoY
Net profit-$11.56M-74.5% YoY
Diluted EPS-$0.18+18.2% YoY
Free cash flow-$11.76M-116.2% YoY
Operating cash flow-$11.74M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-7.1MSep '24$-4.8MDec '24$-4.5MMar '25$-6.6MJun '25$-7.6MSep '25$-10.7MDec '25$-10.1MMar '26$-11.6MJun '26

Diluted EPS by quarter

-0.24Sep '24-0.16Dec '24-0.15Mar '25-0.22Jun '25-0.24Sep '25-0.28Dec '25-0.18Mar '26-0.18Jun '26

Free cash flow by quarter

$-4.3MSep '24$-2.0MDec '24$-1.8MMar '25$-5.4MJun '25$-6.3MSep '25$-11.2MDec '25$-9.9MMar '26$-11.8MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-34.2%
Return on assets-31.3%
Return on invested capital-34.9%
Current ratio25.13
Liabilities / assets4.3%
Cash & investments$232.11M
Total debt$890,638.00
Net cash (debt)$231.22M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $12.46M $10.80M $29.96M $10.89M $7.66M
Selling and Admin Expenses $7.12M $4.82M $13.70M $5.17M $3.08M
-General & Admin Expense $7.12M $4.82M $13.70M $5.17M $3.08M
Research & Development $5.33M $5.98M $16.26M $5.73M $4.58M
Operating Profit -$12.46M -$10.80M -$29.96M -$10.89M -$7.66M
Net Non-Operating Interest Income (Expense) $913,663.00 $717,168.00 $555,526.00 $216,712.00 $84,539.00
Non-Operating Interest Income $913,663.00 $717,168.00 $555,526.00 $216,712.00 $84,539.00
Pretax Profit -$11.54M -$10.09M -$29.40M -$10.68M -$7.58M
Tax $14,322.00 $0.00 $37,724.00 $11,266.00 $7,722.00
Net Profit -$11.56M -$10.09M -$29.44M -$10.69M -$7.59M
Profit from Continuing Operations -$11.56M -$10.09M -$29.44M -$10.69M -$7.59M
Net Income to Parent Company -$11.56M -$10.09M -$29.44M -$10.69M -$7.59M
Net Income to Common Stockholders -$11.56M -$10.09M -$29.44M -$10.69M -$7.59M
Basic EPS -$0.18 -$0.18 -$0.89 -$0.28 -$0.24
Diluted EPS -$0.18 -$0.18 -$0.89 -$0.28 -$0.24
Minority Interests – – $0.00 $0.00 $0.00

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $239.11M $95.82M $104.84M $104.84M $20.08M
Total Current Assets $233.79M $92.27M $101.24M $101.24M $16.58M
Cash and Cash Equivalents & Short-Term Investments $232.11M $90.58M $100.41M $100.41M $15.95M
-Cash and Cash Equivalents $225.49M $79.25M $93.93M $93.93M $15.95M
-Short Term Investments $6.62M $11.33M $6.48M $6.48M –
Prepaid Assets $1.40M $1.36M $677,608.00 $677,608.00 $504,208.00
Other Current Assets $279,172.00 $335,739.00 $150,721.00 $150,721.00 $132,764.00
Total Non-Current Assets $5.32M $3.54M $3.60M $3.60M $3.50M
Net PPE $3.25M $3.36M $3.49M $3.49M $3.36M
-Gross PPE $3.72M $3.74M $3.78M $3.78M $3.61M
-Accumulated Depreciation -$475,571.00 -$384,579.00 -$293,001.00 -$293,001.00 -$240,888.00
Investments and Advances $2.05M – – – –
Non-Current Deferred Assets $0.00 $164,723.00 $93,630.00 $93,630.00 $111,689.00
Other Non-Current Assets $20,418.00 $20,418.00 $20,418.00 $20,418.00 $20,418.00
Total Liabilities $10.19M $11.45M $11.04M $11.04M $11.82M
Total Current Liabilities $9.30M $10.54M $10.11M $10.11M $10.85M
Payables $5.28M $4.73M $5.44M $5.44M $7.05M
-Accounts Payable $5.28M $4.73M $5.44M $5.44M $7.05M
Current Accrued Expenses $3.74M $4.80M $3.59M $3.59M $3.22M
Short-Term Debt and Capital Lease Obligation $111,114.00 $125,392.00 $139,339.00 $139,339.00 $141,282.00
-Current Capital Lease Obligation $111,114.00 $125,392.00 $139,339.00 $139,339.00 $141,282.00
Total Non-Current Liabilities $890,638.00 $912,343.00 $933,625.00 $933,625.00 $965,053.00
Long Term Debt and Capital Lease Obligation $890,638.00 $912,343.00 $933,625.00 $933,625.00 $965,053.00
-Long Term Capital Lease Obligation $890,638.00 $912,343.00 $933,625.00 $933,625.00 $965,053.00
Total Equity $228.92M $84.36M $93.80M $93.80M $8.26M
Stockholders' Equity $228.92M $84.36M $93.80M $93.80M $8.26M
Capital Stock $7,160.00 $5,307.00 $5,301.00 $5,301.00 $3,311.00
-Common Stock $7,160.00 $5,307.00 $5,301.00 $5,301.00 $3,311.00
Additional Paid-In Capital $355.00M $198.90M $198.29M $198.29M $102.07M
Retained Earnings -$126.11M -$114.55M -$104.46M -$104.46M -$93.78M
Less: Treasury Stock $99,963.00 $99,963.00 $99,963.00 $99,963.00 $99,963.00
Gains/Losses Not Affecting Retained Earnings $118,720.00 $105,636.00 $60,160.00 $60,160.00 $62,464.00
Receivables – – $0.00 $0.00 $0.00
-Taxes Receivable – – $0.00 $0.00 $0.00
Minority Interests – – $0.00 $0.00 $0.00
-Preferred Stock – – – – $0.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$11.74M -$9.83M -$23.93M -$11.03M -$5.91M
Net cash flow from continuing operations -$11.74M -$9.83M -$23.93M -$11.03M -$5.91M
Net Income from Continuing Operations -$11.56M -$10.09M -$29.44M -$10.69M -$7.59M
Gain/Loss from Continuing Operations -$38,683.00 $23,505.00 – – –
Depreciation & Depletion & Amortization $130,884.00 $130,766.00 $364,501.00 $90,631.00 $134,855.00
Change in Working Capital -$1.25M -$470,342.00 $2.70M -$1.00M $1.07M
-Change in Receivables $725.00 -$725.00 $2.06M $12,379.00 $21,564.00
-Change in Prepaid Assets $12,044.00 -$866,595.00 -$286,729.00 -$191,348.00 $50,572.00
-Change in Payables and Accrued Expense -$1.23M $432,207.00 $1.03M -$790,864.00 $1.04M
-Change in Other Current Liabilities -$35,983.00 -$35,229.00 -$98,006.00 -$33,371.00 -$32,667.00
Net cash flow from investing $2.67M -$4.80M -$7.21M -$6.65M -$372,456.00
Net Cash Flow from Continuing Investing Activities $2.67M -$4.80M -$7.21M -$6.65M -$372,456.00
Net PPE Purchase and Sale -$21,043.00 -$32,486.00 -$732,925.00 -$165,126.00 -$372,456.00
Net Investment Purchase and Sale $2.69M -$4.77M -$6.48M – –
Financing Cash Flow $155.28M -$37,561.00 $107.39M $95.67M $10.61M
Net Cash Flow from Continuing Financing Activities $155.28M -$37,561.00 $107.39M $95.67M $10.61M
Proceeds from Stock Option Exercised $452,362.00 $33,532.00 $131,142.00 $124,802.00 $516.00
Ending Cash Balance $225.49M $79.25M $93.93M $93.93M $15.95M
Net Change in Cash $146.22M -$14.67M $76.24M $77.99M $4.33M
Beginning Cash Balance $79.25M $93.93M $17.68M $15.95M $11.64M
Effect of Exchange Rate Changes $24,665.00 -$12,813.00 $3,842.00 -$11,745.00 -$20,552.00
Free Cash Flow -$11.76M -$9.86M -$24.66M -$11.19M -$6.28M
Net Other Financing Charges – -$71,093.00 -$136,999.00 $29,756.00 –
-Change in Other Current Assets – – $0.00 $0.00 –
Net Common Stock Issuance – – $107.39M $95.51M $10.77M

Discussion

No comments yet — be the first to weigh in on IMMX.

Leave a comment

Scroll to Top